Download PDF
Fortschr Neurol Psychiatr 2007; 75(4): 199-210
DOI: 10.1055/s-2006-944295
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

40 Jahre Beta-Blocker in der Psychiatrie

40 Years Beta-Adrenoceptor Blockers in PsychiatryJ.  Kornischka1 , J.  Cordes2 , M.  W.  Agelink1
  • 1Klinik für Psychiatrie, Psychotherapie und Psychosomatik am Klinikum Herford
  • 2Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf
Further Information

Publication History

Publication Date:
02 January 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Beta-Blocker gehören zu den erfolgreichsten Substanzklassen der Medizin. Meist werden sie in der Inneren Medizin eingesetzt. In der Psychiatrie wurden Beta-Blocker erstmals vor 40 Jahren bei Angstpatienten angewandt. Seitdem wurde die Wirksamkeit von Beta-Blockern bei schizophrenen und manischen Psychosen, bei vegetativen Entzugssymptomen und bei aggressiven Verhaltensstörungen untersucht. Ebenso werden Beta-Blocker bei unerwünschten Wirkungen von Psychopharmaka, wie Neuroleptika- oder Antidepressiva-induzierten Tachykardien, Lithium-induziertem Tremor, Neuroleptika-induzierter Akathisie sowie bei Spätdyskinesien eingesetzt. Seit Mitte der 90er Jahre wurden Augmentationsstrategien einer antidepressiven Pharmakotherapie mit dem serotonerg wirksamen Beta-Blocker Pindolol entwickelt. Traumatische Gedächtnisinhalte werden unter noradrenerger Aktivierung vermutlich vermehrt gespeichert. Aus diesem Grund wird der lipidlösliche, die Bluthirnschranke gut passierende Beta-Blocker Propranolol seit einigen Jahren bei Patienten mit posttraumatischer Belastungsstörung (PTSD) versuchsweise eingesetzt. Basierend auf einer umfassenden Literaturübersicht diskutiert der vorliegende Artikel sämtliche Indikationen für Beta-Blocker im Bereich der Psychiatrie. Unter Berücksichtigung evidenzbasierter Leitlinienaspekte sind Beta-Blocker beim Lithium-induzierten Tremor, bei Neuroleptika-induzierter Akathisie und bei aggressivem Verhalten von Patienten mit hirnorganischen Störungen indiziert.

Abstract

Beta-adrenoceptor blockers belong to the most successful drug classes of medicine. Mainly they are used in internal medicine. 40 years ago beta-adrenoceptor blockers have occasionally been used in psychiatry for the treatment of anxiety disorders. Over the past four decades, the effects of beta-adrenoceptor blockers in the treatment of schizophrenic and manic psychoses, withdrawal syndromes and aggressive behaviour with temper outbursts has been investigated. Beta-adrenoceptor blockers are also used in the treatment of side-effects of psychopharmacological agents like neuroleptic or antidepressant-induced tachycardias, lithium-induced tremor, antipsychotic-induced akathisia or tardive dyskinesia as well. Since the mid-nineties it has been attempted to improve the efficacy of antidepressant agents by means of the 5-HT-1a-receptorantagonist pindolol. Presumedly memory consolidation of traumatic events can be enhanced by adrenergic activation. Therefore some open clinical trials investigated the effects of propranolol, a lipid soluble drug, which crosses the blood-brain barrier easily, to reduce the manifestation of PTSD. The present review presents the results of the literature with respect to the indications for beta-blockers in psychiatry. Considering evidence-based-medicine criteria beta-blockers are indicated to treat lithium-induced tremor, antipsychotic-induced akathisia and to reduce aggressive behavior of patients with brain-injuries.

Schlüsselwörter

Beta-Blocker - Psychiatrische Erkrankungen - Antiaggressive Wirkungen - Lithium-induzierter Tremor - Akathisie - Tardive Dyskinesien - Pindolol-Augmentation von Antidepressiva - Posttraumatische Belastungsstörung (PTSD)

Key words

beta-adrenoceptor blockers - psychiatric disorders - antiaggressive effects - lithium-induced tremor - akathisia, tardive dyskinesia - pindolol-augmentation of antidepressant agents - posttraumatic-stress disorder (PTSD)

Literatur

  • 1 Granville-Grossman K L, Turner P. The effect of propranolol and anxiety.  Lancet. 1966;  1 788-790
    PubMedGoogle Scholar
  • 2 Modestin J. Beta-Rezeptorenblocker in der Psychiatrie.  Fortschr Neurol Psychiat. 1976;  44 579-596
    PubMedGoogle Scholar
  • 3 Floru L. Die Anwendung betablockierender Substanzen in der Psychiatrie und Neurologie.  Fortschr Neurol Psychiat. 1977;  45 112-127
    PubMedGoogle Scholar
  • 4 Borchard U. Beta-Rezeptoren-Blocker. Definition, Einteilung, Chemie, Pharmakologie, Neurobiochemie, Wirkmechanismus. In: Riederer P, Laux G, Pöldinger W (Hrsg). Neuropsychopharmaka Bd. 6. Wien, New York: Springer 1993: 99-110
    Google Scholar
  • 5 Jefferson J W. Beta-adrenergic receptor blocking drugs in psychiatry.  Arch Gen Psychiatry. 1974;  31 681-691
    PubMedGoogle Scholar
  • 6 Whitlock F A, Price J. Use of beta-adrenergic receptor blocking drugs in psychiatry.  Drugs. 1974;  8 109-124
    PubMedGoogle Scholar
  • 7 Kelly D. Clinical review of beta-blockers in anxiety.  Pharmacopsychiatry. 1980;  13 259-266
    PubMedGoogle Scholar
  • 8 Suzman M M. Use of beta-adrenergic receptor blocking agents in psychiatry. In: Palmer CG (ed). Neuro-pharmacology of central nervous system and behavioral disorders. London, New York: Academic Press 1980: 339-391
    Google Scholar
  • 9 Lader M. Beta-adrenoceptor antagonists in Neuropsychiatry: an update.  J Clin Psychiatry. 1988;  49 213-223
    PubMedGoogle Scholar
  • 10 Wetzel H, Benkert O. Beta-Blocker bei psychiatrischen Erkrankungen. In: Grosdanoff P, Kaindl F, Kraupp O, Lehnert T, Lichtlen P, Schuster J, Siegenthaler W (Hrsg). Beta-Rezeptoren und Beta-Rezeptorenblocker. Berlin, New York: De Gruyter 1988: 339-349
    Google Scholar
  • 11 Gastpar M, Rimpel J. Beta-Rezeptoren-Blocker. Klinik. In: Riederer P, Laux G, Pöldinger W (Hrsg). Neuro-Psychopharmaka. Bd. 6. Wien, New York: Springer 1993: 111-124
    Google Scholar
  • 12 Gleiter C H, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers.  Pharmacopsychiat. 1996;  29 201-211
    PubMedGoogle Scholar
  • 13 Bailly D. The role of Beta-adrenoceptor blockers in the treatment of psychiatric disorders.  CNS Drugs. 1996;  5 115-136
    PubMedGoogle Scholar
  • 14 Atsmon A, Blum I. Treatment of acute porphyria variegata with propranolol.  Lancet. 1970;  1 196-197
    PubMedGoogle Scholar
  • 15 Schwarz D, Martin J. Die Anwendung von Propranolol bei der akuten intermittierenden Porphyrie.  Nervenarzt. 1973;  44 648-651
    PubMedGoogle Scholar
  • 16 Emrich H M. ZNS-Aktivität von Beta-Rezeptorenblockern und ihre Anwendung in der Neurologie und Psychiatrie-interdisziplinäre Bewertung. München, Bern, Wien: Zuckschwerdt 1985: 65-75
    Google Scholar
  • 17 Delini-Stula A, Meier M. Inhibitory effects of propranolol and oxprenolol on excitation by a MAO inhibitor and reserpine in the mouse.  Neuropharmacol. 1976;  15 383-388
    CrossrefPubMedGoogle Scholar
  • 18 Vassout A, Delini-Stula A. Effects de beta-bloquers (propranolol et oxprenolol) et du diazepam sur differrents modeles d'aggressivité chez le rat.  J Pharmacol (paris). 1977;  8 5-14
    PubMedGoogle Scholar
  • 19 Bernasconi R. The GABA hypothesis of affective illness. Influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aldenhoff JB, Lux HD (eds). Basic mechanisms in the action of lithium. Amsterdam: Excerpta Medica 1982: 183-192
    Google Scholar
  • 20 Berlant J L. One more look at propranolol for treatment of refractory schizophrenia.  Schizophr Bull. 1987;  13 705-714
    PubMedGoogle Scholar
  • 21 Wahlbeck K, Cheine M V, Gibody S, Ahonen J. Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials.  Schizophrenia Research. 2000;  41 341-347
    CrossrefPubMedGoogle Scholar
  • 22 Atsmon A, Blum I, Steiner M, Latz A, Wijsenbeck H. Further studies with propranolol.  Lancet. 1970;  1 196-197
    PubMedGoogle Scholar
  • 23 Volk W, Bier W, Braun J P, Grüter W, Spiegelberg U. Behandlung von erregten Psychosen mit einem Beta-Rezeptorenblocker (Oxprenolol) in hoher Dosierung.  Nervenarzt. 1972;  43 491-492
    PubMedGoogle Scholar
  • 24 Rackensberger W, Fritsch W, Schwarz D, Stutte K H, Zerssen D v. Wirkung des Beta-Blockers Propranolol auf Manien.  Arch Psychiat Nervenkr. 1976;  222 222-243
    PubMedGoogle Scholar
  • 25 Emrich H M, Zerssen Dv Möller H J, Kissling W, Cording C, Schietsch H J, Riedel E. Action of propranolol in mania: comparison of effects on the d- and i-stereoisomer.  Pharmacopsychiat. 1979;  12 295-304
    PubMedGoogle Scholar
  • 26 Tyrer P J. Use of beta-blocking drugs in psychiatry and neurology.  Drugs. 1980;  20 300-308
    PubMedGoogle Scholar
  • 27 Rosenthal N E, Jacobsen F M, Sack D A, Arendt J, James S P, Parry B, Wehr T. Atenolol in seasonal affective disorder: a test of the melatonin hypothesis.  Am J Psychiatry. 1988;  154 534-535
    PubMedGoogle Scholar
  • 28 Schlager D S. Early-morning administration of short-acting beta-blockers for treatment of winter depression.  Am J Psychiatry. 1994;  151 1383-1385
    PubMedGoogle Scholar
  • 29 Rausch J L, Janowski D S, Golshan S, Kuhn K, Risch S C. Atenolol treatment of late luteal phase disorder.  J Affective Disord. 1988;  15 141-147
    CrossrefPubMedGoogle Scholar
  • 30 Agelink M W, Dammers S, Malessa R, Leonhardt M, Zitzelsberger A, Ullrich H, Zeit T. Nutzen und Risiken der Elektrokrampfbehandlung (EKT) bei älteren Patienten mit kardiovaskulären Risikofaktoren.  Nervenarzt. 1998;  69 70-75
    CrossrefPubMedGoogle Scholar
  • 31 Stoudemire A, Knos G, Gladson M, Markwalter H, Sung Y F, Morris R, Cooper R. Labetalol in the control of cardiovascular response to electroconvulsive therapy in high-risked depressed medical patients.  J Clin Psychiatry. 1990;  51 508-512
    PubMedGoogle Scholar
  • 32 Gaines G Y, Rees D I. Anesthetic considerations for electro-convulsive therapy.  South Med J. 1992;  85 469-482
    PubMedGoogle Scholar
  • 33 Figiel G S, DeLeo B, Zorumski C F, Baker K, Goewert A, Jarvis M, Smith D S, Mattingly G, Ruwitch J. Combined use of labetalol and nifedipine in controlling the cardiovascular response from ECT.  J Geriatr Psychiatry Neurol. 1993;  6 20-24
    PubMedGoogle Scholar
  • 34 Castelli I, Steiner L A, Kaufmann M A, Alfille P H, Schouten R, Welch C A, Drop L J. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy.  Anesth Analg. 1995;  80 557-561
    PubMedGoogle Scholar
  • 35 London S W, Glass D D. Prevention of electroconvulsive therapy-induced dysrhythmias with atropine and propranolol.  Anestesiology. 1985;  62 819-822
    PubMedGoogle Scholar
  • 36 Hawken E R, Delva N J, Lawson J S. Sucessfull use of propranolol in migraine associated with electroconvulsive therapy.  Headeache. 2001;  41 92-96
    PubMedGoogle Scholar
  • 37 Kales A, Cadieux R, Soldatos C R, Tan T L. Sucessful treatment of narcolepsy with propranolol.  Arch Neurol. 1979a;  36 650-651
    PubMedGoogle Scholar
  • 38 Kales A, Soldatos C R, Cadieux R, Bixler E O, Tan T L, Sharf M B. Propranolol in the treatment of narcolepsy.  Ann Intern Med. 1979b;  91 741-743
    PubMedGoogle Scholar
  • 39 Meier-Ewert K, Matsubayashi K, Benter L. Propranolol: long-term treatment in narcolepsy-cataplaxy.  Sleep. 1985;  8 95-104
    PubMedGoogle Scholar
  • 40 De Leersnyder H, De Blois M C, Vekemans M, Sidi D, Villian E, Kindermans C, Munnich A. Beta-1-adrenergic antagonists improve sleep and behavioral disturbances in a circadian disorder, Smith-Magenis syndrome.  J Med Genet. 2001;  38 586-590
    CrossrefPubMedGoogle Scholar
  • 41 De Leersnyder H, De Blois M C, Bresson J L, Sidi D, Claustrat B, Munnich A. Inversion of the circadian melatonin rhythm in Smith-Magenis syndrome.  Rev Neurol (Paris). 2003a;  159 (Suppl) 6S21-S26
    PubMedGoogle Scholar
  • 42 De Leersnyder H, Bresson J L, De Blois M C, Souberbielle J C, Mogenet A, Delhotal-Landes B, Salefranque F, Munnich A. Beta-1-adrenergic antagonists and metatonin reset the clock and restore sleep in a circadian disorder, Smith Magenis syndrome.  J Med Genet. 2003b;  40 74-78
    CrossrefPubMedGoogle Scholar
  • 43 Shevitz S A, Jameison R C, Petrie W M, Cook J E. Compulsive water drinking treated with high dose propranolol.  J Nerv Ment Dis. 1980;  168 246-248
    PubMedGoogle Scholar
  • 44 Goldstein M B, Folsom T. The sucessful treatment of psychogenic polydipsia and water intoxication with propranolol. A case report.  Minn Med. 1991;  74 29-32
    PubMedGoogle Scholar
  • 45 Kishi Y, Kurosawa H, Endo S. Is propranolol effective in primary polydipsia?.  Int J Psychiatry Med. 1998;  28 315-325
    PubMedGoogle Scholar
  • 46 Steinert T. Neuere Tendenzen in der Pharmakotherapie aggressiven Verhaltens bei psychisch Kranken.  Fortschr Neurol Psychiatr. 1992;  60 393-400
    PubMedGoogle Scholar
  • 47 Steinert T. Aggression. In: Faust V (Hrsg). Psychiatrie. Ein Lehrbuch für Klinik, Praxis und Beratung. Stuttgart, Jena, New York: G. Fischer 1995: 483-400
    Google Scholar
  • 48 Volavka J. Can aggressive behaviour in humans be modified by beta blockers?.  Postgrad Med. 1988;  163 8
    PubMedGoogle Scholar
  • 49 Elliot F A. Propranolol for control belligerent behavior following acute brain damage.  Ann Neurol. 1976;  1 489-491
    PubMedGoogle Scholar
  • 50 Schreier H A. Use of propranolol in the treatment of postencephalitic psychosis.  Am J Psychiatry. 1979;  139 840-841
    PubMedGoogle Scholar
  • 51 Yudofsky S C, Williams D, Gorman J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes.  Am J Psychiatry. 1981;  138 218-220
    CrossrefPubMedGoogle Scholar
  • 52 Mansheim P. Treatment with propranolol of the behavioral sequelae of brain damage.  J Clin Psychiatry. 1981;  42 132
    PubMedGoogle Scholar
  • 53 Ratey J J, Morrill R, Oxenkrug G. Use of propranolol and unprovoked episodes of rage.  Am J Psychiatry. 183;  140 1356-1357
    PubMedGoogle Scholar
  • 54 Yudofsky S C, Stevens L, Silver J, Barsa J, Williams D. Propranolol in the treatment of rage and violent behavior associated with korsakoff psychosis.  Am J Psychiatry. 1984;  141 114-115
    PubMedGoogle Scholar
  • 55 Roach N E, George M D, Skoch M G. Propranolol for episodic dyscontrol syndrome.  J Kans Med Soc. 1984;  85 240-241
    PubMedGoogle Scholar
  • 56 Jenkins S C, Maruta T. Therapeutic use of propranolol for intermittant explosive behavior.  Mayo Clin Proc. 1987;  62 204-214
    PubMedGoogle Scholar
  • 57 Ratey J J, Mikkelsen E, Sorgi P, Zuckerman H S, Polakoff S, Bemporad J, Bick P, Kadish W. Autism: the treatment of aggressive behaviors.  J Clin Psychopharmacol. 1987a;  7 35-41
    PubMedGoogle Scholar
  • 58 Ratey J J, Bemporad J, Sorgi P, Bick P, Polakoff S, O'Drisdoll G, Mikkelsen E. Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults.  J Autism Dev Disord. 1987b;  17 439-446
    PubMedGoogle Scholar
  • 59 Stewart J T, Mounts M L, Clark J L. Aggressive behavior in Huntington' disease: treatment with propranolol.  J Clin Psychiatry. 1987;  48 385-386
    PubMedGoogle Scholar
  • 60 Abraham G, Jarett M B. Propranolol in the treatment of postencephalitic psychosis.  Can J Psychiatry. 1990;  35 104-105
    PubMedGoogle Scholar
  • 61 Ruedrich S L, Grush L, Wilson J. Beta-adrenergic blocking medications for aggressive or self-injurious mentally retarded persons.  Am J Ment Retard. 1990;  95 110-119
    PubMedGoogle Scholar
  • 62 Sims J, Galvin M R. Pediatric psychopharmacologic uses of propranolol.  J Child Adol Psychiatric Ment Health Nurs. 1990;  3 18-24
    PubMedGoogle Scholar
  • 63 Cohen I L, Tsiouris J A, Pfadt A. Effect of long-acting propranolol on agonistic and stereotypical behaviors in a man with pervasive developmental disorder and fragile-X-Syndrome: a double-blind, placebo-controlled study.  J Clin Psychopharmacol. 1991;  11 398-399
    PubMedGoogle Scholar
  • 64 Lang C, Remington D. Treatment of impulsive and aggressive behavior in a blind, deaf, retarded adolescent.  J Am Acad Child Adolesc Psychiatry. 1994;  33 265-269
    PubMedGoogle Scholar
  • 65 Steinert T. Behandlung autoaggressiver Erregungszustände bei geistiger Behinderung mit Propranolol.  Psychopharmakotherapie. 1998;  5 26-28
    PubMedGoogle Scholar
  • 66 Reynolds E H. The pharmacological management of epilepsy associated with psychological disorders.  Br J Psychiatry. 1982;  141 549-557
    PubMedGoogle Scholar
  • 67 Williams D T, Mehl R, Yudofsky S, Adams D, Roseman B. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction.  J Am Acad Child Psychiatry. 1982;  21 129-135
    PubMedGoogle Scholar
  • 68 Leon Z, Alonso J L, Basterrechea L. Acción del propranolol en la agresividad de los oligofrénicos encefalopáticos.  J Int Defectologia en el Hogar de Impedidos Físicos y Mentales. 1983;  4 431-436
    PubMedGoogle Scholar
  • 69 Mattes J A, Rosenberg J, Mays D. Carbamazepine versus propranolol in patients with uncontrolled rage outbursts: a random assignment study.  Psychopharmacol Bull. 1984;  20 98-100
    PubMedGoogle Scholar
  • 70 Greendyke R M, Schuster D B, Wooton J A. Propranolol in the treatment of assautive patients with organic brain disease.  J Clin Psychopharmacol. 1984;  4 282-284
    PubMedGoogle Scholar
  • 71 Ratey J J, Mikkelsen E J, Smith G B, Upadhyaya A, Zuckerman H S, Martell D, Sorgi P, Polakoff S, Bemporad J. Beta blockers in the severely and profoundly mentally retarded.  J Clin Psychopharmacol. 1986;  6 103-107
    PubMedGoogle Scholar
  • 72 Kuperman S, Stewart M. Use of propranolol to decrease aggressive outbursts in younger patients.  Psychosomatics. 1987;  28 315-319
    PubMedGoogle Scholar
  • 73 Luchins D J, Dojka M S. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded.  Psychopharmacol Bull. 1989;  25 372-375
    PubMedGoogle Scholar
  • 74 Silver J M, Yudofsky S C, Slater J A, Kugelmass-Gold R, Katz-Stryrer B L, Williams D T, Wolland H, Endicott J. Propranolol treatment of chronically hospitalized aggressive patients.  J Neuropsychiatry Clin Neurosci. 1999;  11 328-335
    PubMedGoogle Scholar
  • 75 Greendyke R M, Kanter D R, Schuster D B, Verstraete S, Wooton J. Propranolol in the treatment of assaultive patients with organic brain disease.  J Nerv Ment Dis. 1986;  174 290-294
    CrossrefPubMedGoogle Scholar
  • 76 Greendyke R M, Berkner J P, Webster J C, Gulya A. Treatment of behavioral problems with pindolol.  Psychosomatics. 1989;  30 161-165
    PubMedGoogle Scholar
  • 77 Greendyke R M, Kanter D R. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study.  J Clin Psychiatry. 1986;  47 423-426
    PubMedGoogle Scholar
  • 78 Brooke M M, Pattersen D R, Questad K A, Cardenas D, Farrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury.  Arch Phys Med Rehabil. 1992;  73 917-921
    PubMedGoogle Scholar
  • 79 Petrie W M, Ban T A. Propranolol in organic agitation.  Lancet. 1981;  1 324
    PubMedGoogle Scholar
  • 80 Jenike M A. Treating the violent elderly patient with propranolol.  Geriatrics. 1983;  38 29-31
    PubMedGoogle Scholar
  • 81 Salzman C. Treating of the agitated demented elderly patient.  Hosp Community Psychiatry. 1988;  39 1143-1144
    PubMedGoogle Scholar
  • 82 Weiler P G, Mungas D, Bernick C. Propranolol for control of disruptive behavior in senile dementia.  J Geriatr Psychiatry and Neurol. 1988;  1 226-230
    CrossrefPubMedGoogle Scholar
  • 83 Jensen J F. Hypersexual agitation in Alzheimer's disease.  J Am Geriatr Soc. 1989;  27 917
    PubMedGoogle Scholar
  • 84 Schneider L S, Solin P B. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia:.  a selective review. Int J Geriatr, Psychiatry. 1191;  6 691-708
    PubMedGoogle Scholar
  • 85 Maletta G J. Treatment of behavioral symptomatology of Alzheimer's disease with emphasis on aggression. Current clinical approaches.  Int Psychogeriatr. 1992;  4 (Suppl 1) 117-130
    PubMedGoogle Scholar
  • 86 Peskind E R, Tsuang D W, Bonner L T, Pascualy M, Riekse R G, Snowdon M B, Thomas R, Raskind M A. Propranolol for disruptive behaviors in nursing home residents with problable or possible Alzheimer disease: a placebo-controlled study.  Alzheimer Dis Assoc Disord. 2005;  19 23-28
    CrossrefPubMedGoogle Scholar
  • 87 Williams D T, Mehl R, Yudofsky S, Adams D, Roseman B. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction.  J Am Acad Child Psychiatry. 1982;  21 129-135
    PubMedGoogle Scholar
  • 88 Wender P H. Concurrent therapy with d-amphetamine and adrenergic drugs.  Am J Psychiatry. 1986;  143 259-260
    PubMedGoogle Scholar
  • 89 Mattes J A. Propranolol for adults with temper outbursts and residual attention deficit disorder.  J Clin Psychopharmacol. 1986;  6 299-302
    PubMedGoogle Scholar
  • 90 Mattes J A. Carbamazepine vs. propranolol for rage outbursts.  Psychopharmacol Bull. 1988;  24 179-182
    PubMedGoogle Scholar
  • 91 Mattes J A. Comparative effectiveness of carbamazepine and propranolol for rage outbursts.  J Neuropsychiatry Clin Neurosci. 1990;  2 159-164
    PubMedGoogle Scholar
  • 92 Ratey J J, Greenberg M S, Lindem K J. Combination treatment for attention deficit hyperactivity disorder in adults.  J Nerv Ment Dis. 1991;  179 699-701
    PubMedGoogle Scholar
  • 93 Buitellaar J K, Gaag R J van der, Swaab-Barneveld H, Kuiper M. Pindolol and methylphenidate in children with attention-deficit-hyperactivity disorder. Clinical efficacy and side-effects.  J Clin Psychol Psychiat. 1996;  37 587-595
    PubMedGoogle Scholar
  • 94 Jenkins S C, Maruta T. Therapeutic use of propranolol for intermittant explosive behavior.  Mayo Clin Pro. 1987;  62 204-214
    PubMedGoogle Scholar
  • 95 Grizenko N, Vida S. Propranolol treatment of episodic dyscontrol and aggressive behavior in children.  Can J Psychiatry. 1988;  33 776-778
    PubMedGoogle Scholar
  • 96 Kastner T, Burlingham K, Friedman D L. Metoprolol for aggressive behavior in persons with mental retardation.  Am Fam Physician. 1990;  42 1585-1588
    PubMedGoogle Scholar
  • 97 Arnold L E, Aman M G. Beta blockers in mental retardation and developmental disorders.  J Child Adolesc Psychopharmacology. 1991;  1 361-373
    PubMedGoogle Scholar
  • 98 Matthews-Ferrari K, Karroum N. Metoprolol for aggression.  J Am Acad Child Adolesc Psychiatry. 1992;  31 994
    CrossrefPubMedGoogle Scholar
  • 99 Connor D F. Beta-blockers for aggression: a review of the pediatric experience.  J Child Adolesc Psychopharmacology. 1993;  3 99-114
    PubMedGoogle Scholar
  • 100 Riddle M A, Bernstein G A, Cook E H, Leonhard H L, March J S, Swanson J M. Anxiolytics, adrenergic agents and naltrexone.  J Am Acad Child Adolesc Psychiatry. 1999;  38 546-556
    PubMedGoogle Scholar
  • 101 Whitman J R, Maier G J, Eichelman B. Beta-blockers for aggressive behavior in schizophrenia.  Am J Psychiatry. 1987;  144 538
    PubMedGoogle Scholar
  • 102 Sorgi P J, Ratey J J, Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia.  Am J Psychiatry. 1986;  143 775-776
    PubMedGoogle Scholar
  • 103 Pugh C R, Steinert J, Priest R G. Propranolol in schizophrenia: a double-blind placebo-controlled trial of propranolol as an adjunct to neuroleptic medication.  Br J Psychiatry. 1983;  143 151-155
    PubMedGoogle Scholar
  • 104 Ritrovato C A, Weber S S, Dufresne R L. Nadolol in the treatment of aggressive behavior associated with schizophrenia.  Clin Pharm. 1989;  8 132-135
    PubMedGoogle Scholar
  • 105 Alpert M, Allan E R, Citrome L, Laury G, Sudilovsky A. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients.  Psychopharmacol Bull. 1990;  26 367-371
    PubMedGoogle Scholar
  • 106 Ratey J J, Sorgi P, O'Driscoll G A, Sands S, Daehler M, Fletcher J R, Kadish W, Spuiell G, Polakoff S, Lindem K, Bemporad J R, Richardson L, Rosenfeld B. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.  J Clin Psychiatry. 1992;  53 41-46
    PubMedGoogle Scholar
  • 107 Allan E R, Alpert M, Sison C E, Citrome L, Laury G, Bermann I. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.  J Clin Psychiatry. 1996;  57 455-459
    CrossrefPubMedGoogle Scholar
  • 108 Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H, Hirschman S, Ritsner M. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study.  Int Clin Psychopharmacology. 2001;  16 111-115
    CrossrefPubMedGoogle Scholar
  • 109 Floru L. Klinische Behandlungsversuche des lithiumbedingten Tremors durch Betarezeptorantagonisten (Propranolol).  Int Pharmacopsychiat. 1971;  6 197-222
    PubMedGoogle Scholar
  • 110 Kirk L, Baastrup P C, Schou M. Propranolol and lithium-induced tremor.  Lancet. 1972;  1 839
    PubMedGoogle Scholar
  • 111 Kirk L, Baastrup P C, Schou M. Propranolol treatment of lithium-induced tremor.  Lancet. 1973a;  2 1086-1087
    PubMedGoogle Scholar
  • 112 Kirk L, Baastrup P C, Schou M. Propranololbehandlung bei Lithiumtremor.  Nervenarzt. 1973b;  44 657-658
    PubMedGoogle Scholar
  • 113 Lapierre Y D. Control of lithium tremor with propranolol.  Canad Med Ass. 1976;  114 619-621
    PubMedGoogle Scholar
  • 114 Floru L, Floru L, Tegeler J. Wirkung von Beta-Rezeptorenblockern (Pindolol und Practolol) auf den lithiumbedingten Tremor.  Arzneim Forsch. 1974;  24 1122-1125
    PubMedGoogle Scholar
  • 115 Floru L, Tegeler J, Wolmsen H. Untersuchungen des lithiumbedingten Tremors mit verschiedenen Messmethoden.  Int Pharmacopsychiat. 1979;  14 149-157
    PubMedGoogle Scholar
  • 116 Brosteanu E, Floru L, Kaiser H. Die Behandlung des lithiumbedingten Tremors mit Oxprenolol im Doppelblindversuch gegen Plazebo. In: Kielholz P (Hrsg). Betablocker und Zentralnervensystem. Bern, Stuttgart, Wien: Huber 1978: 187-193
    Google Scholar
  • 117 Gaby N C, Lefkowitz D S, Israel J R. Treatment of lithium tremor with metoprolol.  Am J Psychiatry. 1983;  140 593-595
    PubMedGoogle Scholar
  • 118 Zubenko G S. Comparison of metoprolol and propranolol in the treatment of lithium tremor.  Psychiat Res. 1984;  11 163-164
    CrossrefPubMedGoogle Scholar
  • 119 Davé M. Treatment of lithium induced tremor with atenolol.  Can J Psychiatry. 1989;  34 132-133
    PubMedGoogle Scholar
  • 120 Kruse J M, Ereshefsky L, Scavone M. Treatment of lithium-induced tremor with nadolol.  Clin Pharm. 1984;  3 299-301
    PubMedGoogle Scholar
  • 121 Davé M, Langbart M M. Nadolol for lithium tremor in the presence of liver damage.  Ann Clin Psychiatry. 1994;  6 51-52
    PubMedGoogle Scholar
  • 122 Schou M, Vestergaard P. Use of propranolol during lithium treatment: an enquiry and a suggestion.  Pharmacopsychiat. 1987;  20 131
    PubMedGoogle Scholar
  • 123 Brüne M, Bräunig P. Kompendium der Akathisie. Stuttgart, New York: Thieme 1997a
    Google Scholar
  • 124 Fleischhacker W W, Roth S D, Kane J M. The pharmacologic treatment of neuroleptic-induced akathisia.  J Clin Psycho-pharmacol. 1990;  10 12-21
    PubMedGoogle Scholar
  • 125 Brüne M, Bräunig P. Akathisie.  Fortschr Neurol Psychiat. 1997b;  65 396-406
    PubMedGoogle Scholar
  • 126 Schönecker M. Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.  Nervenarzt. 1957;  27 35
    PubMedGoogle Scholar
  • 127 Lohr J B, Kuczenski R, Niculescu A B. Oxidative mechanisms and tardive dyskinesia.  CNS Drugs. 2003;  17 47-62
    PubMedGoogle Scholar
  • 128 Moreira M JC, Karniol I G. Improvement of tardive dyskinesia with high doses of propranolol: a case report.  Rev Paul Med. 1979;  93 76-78
    PubMedGoogle Scholar
  • 129 Roberts P W. The use of propranolol in treating tardive dyskinesia.  Can Med Assoc J. 1980;  6 1106-1107
    PubMedGoogle Scholar
  • 130 Kulik F A, Wilbur R. Propranolol for tardive dyskinesia and extrapyramidal effects (pseudoparkinsonism) from neuroleptics.  Psychopharmacol Bull. 1980;  16 18-19
    PubMedGoogle Scholar
  • 131 Wilbur R, Kulik F A. Propranolol (Inderal) for tardive dyskinesia and extrapyramidal side effects from neuroleptics.  Prog Neuro Psychopharmacol. 1980;  4 627-632
    PubMedGoogle Scholar
  • 132 Ayd F J. Propranolol therapy for tardive dyskinesia.  Drug Ther Newsletter. 1981;  16 29-31
    PubMedGoogle Scholar
  • 133 Einarson T R. Use of propranolol in treating tardive dyskinesia.  Can Med Assoc J. 1981;  124 1260-1262
    PubMedGoogle Scholar
  • 134 Chaudhry R, Radonjic D, Waters B. Efficacy of propranolol in a patient with tardive dyskinesia and extrapyramidal syndrome.  Am J Psychiatry. 1982;  139 674-676
    PubMedGoogle Scholar
  • 135 Pitts Jr F N. Treatment of tardive dyskinesia with propranolol.  J Clin Psychiatry. 1982;  43 304
    PubMedGoogle Scholar
  • 136 Olivera A A, Kiefer M W. Propranolol therapy in a patient with panic disorder, tardive dyskinesia, and essential tremor.  J Clin Psychiatry. 1984;  45 484-485
    PubMedGoogle Scholar
  • 137 Novac A. Improvement in tardive dyskinesia and MMPI scores with propranolol.  J Clin Psychiatry. 1986;  47 218-219
    PubMedGoogle Scholar
  • 138 Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine.  J Ner Ment Dis. 1993;  181 649-651
    PubMedGoogle Scholar
  • 139 Bacher N M, Lewis H A. Low-dose propranolol in tardive dyskinesia.  Am J Psychiatry. 1980;  137 495-497
    PubMedGoogle Scholar
  • 140 Schrodt Jr G R, Wright J H, Simpson R, Moore D P, Chase S. Treatment of tardive dyskinesia with propranolol.  J Clin Psychiatry. 1982;  43 328-331
    PubMedGoogle Scholar
  • 141 Perenyi A, Farkas A. Propranolol in the treatment of tardive dyskinesia.  Biol Psychiatry. 1983;  18 391-394
    PubMedGoogle Scholar
  • 142 Wright J H, Schrodt G R, Simpson R, Moore D P, Davis B. Propranolol treatment of tardive dyskinesia: preliminary report of a placebo-controlled study. Stockholm: III. World Congress of Biological Psychiatry 1981 Vol. 2: F 528
    Google Scholar
  • 143 Karniol I G, Portera W. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.  Braz J Med Res. 1982;  15 389-394
    PubMedGoogle Scholar
  • 144 Hebenstreit G F, Hoffmann H, Hoffmann W, Pittner H. Betablockade mit Celiprolol bei neuroleptikabehandelten Patienten mit tardiver Dyskinesie.  Wien Klin Wochenschr. 1986;  98 388-392
    PubMedGoogle Scholar
  • 145 Cordes J, Mobascher A, Arends M, Agelink M, Klimke A. Eine neue Methode zur Behandlung von Depressionen: repetitive transkranielle Magnetstimulation.  Dtsch Med Wochenschr. 2005;  130 889-892
    Article in Thieme ConnectPubMedGoogle Scholar
  • 146 de Montigny C, Chaput Y, Blier P. Classical and novel targets for antidepressant drugs.  Intl Acad Biomed and Drug Res. 1993;  5 76-78
    PubMedGoogle Scholar
  • 147 Artigas F, Perez V, Alvarez E. Pindolol induces rapid improvement of depressed patient treated with serotonin reuptake inhibitors.  Arch Gen Psychiatry. 1994;  51 248-251
    PubMedGoogle Scholar
  • 148 Kraus R P. Pindolol augmentation of trancylpromine in psychotic depression.  J Clin Psychopharmacol. 1997;  17 225-226
    CrossrefPubMedGoogle Scholar
  • 149 Bell C, Wilson S, Nutt D J. Pindolol augmentation of sertralin in resistant depression and its effect on sleep.  J Psychopharmacol. 1998;  12 105-107
    PubMedGoogle Scholar
  • 150 Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.  J Clin Psychopharmacology. 1995;  15 217-222
    CrossrefPubMedGoogle Scholar
  • 151 Vinar O, Vinarova E, Horacek J. Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression.  Homeostasis. 1996;  37 93-95
    PubMedGoogle Scholar
  • 152 Bakish D, Hooper C L, Thornton M D, Wiens A, Miller C A, Thibaudeau C A. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.  Int Clin Psychopharmacol. 1997;  12 91-97
    PubMedGoogle Scholar
  • 153 Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT-1A receptors induces rapid antidepressant response.  Neuropsychopharmacology. 1997;  16 333-338
    CrossrefPubMedGoogle Scholar
  • 154 Erfurth A, Kammerer C, Ackenheil M, Möller H J. Effect of pindolol in hastening response to serotonergic anti-depressants: an open study in severely depressed female inpatients.  Eur Neuropsychopharmacol. 1997;  7 (Suppl. 2) S147-147
    PubMedGoogle Scholar
  • 155 Beique J C, Blier P, de Montigny C. Potentiation by (-) pindolol of the activation of postsynaptic 5-HT(1A)-receptors induced by venlafaxine.  Neuropsychopharmacology. 2000;  23 294-306
    CrossrefPubMedGoogle Scholar
  • 156 Dursun S M, Devarajan S, Kutcher S. The “dalhousie serotonin cocktail” for treatment-resistant major depressive disorder.  J Psychopharmacology. 2001;  15 136-138
    PubMedGoogle Scholar
  • 157 Berman R M, Darnell A M, Miller H L, Anand A, Charney D S. Effect of pindolol in hastening response to fluoxetin in the treatment of major depression: a double-blind, placebo-controlled trial.  Am J Psychiatry. 1997;  154 37-43
    PubMedGoogle Scholar
  • 158 Moreno F A, Gelenberg A J, Bachar K, Delgado P L. Pindolol augmentation of treatment-resistant depressed patients.  J Clin Psychiatry. 1997;  58 437-439
    PubMedGoogle Scholar
  • 159 Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.  Lancet. 1997;  349 1594-1597
    CrossrefPubMedGoogle Scholar
  • 160 Berman R M, Anand A, Capiello A, Miller H L, Hu X S, Oren D A, Charney D S. The use of pindolol with fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial.  Biol Psychiatry. 1999;  45 1170-1177
    CrossrefPubMedGoogle Scholar
  • 161 Maes M, Libbrecht I, Hunsel F van, Campens D, Meltzer Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.  J Clin Psychopharmacol. 1999;  19 177-182
    CrossrefPubMedGoogle Scholar
  • 162 Sacristan J A, Gilaberte I, Boto B, Buesching D P, Obenchain R L, Demitrack M, Perez-Sola V, Alvarez E, Artigas F. Cost-effectiveness of fluoxetine plus pindolol in patients with major depression disorder: results from randomized, double-blind clinical trial.  Int Clin Psychopharmacol. 2000;  15 107-113
    PubMedGoogle Scholar
  • 163 Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.  J Clin Psychopharmacol. 1998;  18 441-446
    CrossrefPubMedGoogle Scholar
  • 164 Tome M B, Cloninger C R, Watson J P, Issac M T. Serotonergic autoceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.  J Affect Disord. 1997;  44 101-109
    CrossrefPubMedGoogle Scholar
  • 165 Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, Perez J. How long should pindolol be associated with paroxetine to improve antidepressant response?.  J Clin Psychopharmacol. 1997;  17 446-450
    CrossrefPubMedGoogle Scholar
  • 166 Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial.  Am J Psychiatry. 1998;  155 1346-1351
    PubMedGoogle Scholar
  • 167 Sokolski K N, Conney J C, Brown B J, DeMet E M. Once-daily high-dose pindolol for SSRI-refractory depression.  Psychiatry Res. 2004;  15 (125) 81-86
    PubMedGoogle Scholar
  • 168 Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors.  Arch Gen Psychiatry. 1999;  56 375-379
    CrossrefPubMedGoogle Scholar
  • 169 Perry E B, Berman R M, Sanacora G, Anand A, Lynch-Colonese K, Charney D S. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.  J Clin Psychiatry. 2004;  65 238-243
    PubMedGoogle Scholar
  • 170 Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.  J Affect Disord. 1996;  41 201-210
    CrossrefPubMedGoogle Scholar
  • 171 Isaac M B, Issac M T. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.  Hum Psychopharmacol. 2003;  18 569-574
    PubMedGoogle Scholar
  • 172 Agelink M W, Baumann B, Sanner D, Kavuk I, Mück-Weymann M. Komorbidität zwischen kardiovaskulären Erkrankungen und Depressionen.  Dtsch Med Wochenschr. 2004;  129 697-700
    Article in Thieme ConnectPubMedGoogle Scholar
  • 173 Räsanen P, Hakko H, Tiihonen J. Pindolol and major affective disorders: a three-year follow-up study of 30.485 patients.  J Clin Psychopharmacol. 1999;  19 297-302
    CrossrefPubMedGoogle Scholar
  • 174 Hirschmann S, Dannon P N, Iancu I, Dolberg O T, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial.  J Clin Psychopharmacol. 2000;  20 556-559
    CrossrefPubMedGoogle Scholar
  • 175 Stein M B, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.  Am J Psychiatry. 2001;  158 1725-1727
    CrossrefPubMedGoogle Scholar
  • 176 Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings.  Int Clin Psychopharmacol. 1996;  11 37-44
    PubMedGoogle Scholar
  • 177 Koran L M, Mueller K, Maloney A. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?.  J Clin Psychopharmacol. 1996;  16 253-254
    CrossrefPubMedGoogle Scholar
  • 178 Goodman W K. Obsessive-compulsive disorder: diagnosis and treatment.  J Clin Psychiatry. 1999;  60 (Suppl 18) 27-32
    PubMedGoogle Scholar
  • 179 Dannon P N, Sasson Y, Hirschmann S, Iancu I, Grunhaus L J, Zohar J. Pindolol augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind placebo-controlled trial.  Eur Neuropsychopharmacol. 2000;  10 165-169
    PubMedGoogle Scholar
  • 180 Albert U, Bergesio C, Pessina E, Maina G, Bogetto F. Management of treatment-resistant obsessive-compulsive disorder.  Panminerva Med. 2002;  44 83-91
    PubMedGoogle Scholar
  • 181 Kolb L S, Burris B, Griffith S. Propranolol and clonidine in treatment of the chronic posttraumatic stress disorder of war. In: Van der Kolk (Ed). Posttraumatic stress disorder: psychological and biological sequelae. Waschington DC: American Psychiatric Press 1984: 98-105
    Google Scholar
  • 182 Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type: a pilot study.  Am J Dis Child. 1988;  142 1244-1247
    PubMedGoogle Scholar
  • 183 Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study.  J Trauma Stress. 2002;  15 433-437
    CrossrefPubMedGoogle Scholar
  • 184 Pitman R K, Sanders K M, Zusman R M, Healy A R, Cheema F, Lasko N B, Cahill L, Orr S P. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol.  Biol Psychiatry. 2002;  51 189-192
    CrossrefPubMedGoogle Scholar
  • 185 Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar C R. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma.  Biol Psychiatry. 2003;  54 947-949
    CrossrefPubMedGoogle Scholar
  • 186 Shalev A Y, Sahar T, Freedman S, Peri T, Glick N, Brandes D, Orr S P, Pitman R K. A prospective study of heart rate response following trauma and the subsequent development of posttraumatic stress disorder.  Arch Gen Psychiatry. 1998;  55 553-559
    CrossrefPubMedGoogle Scholar
  • 187 Brayant R A, Harvey A G, Guthrie R M, Moulds M L. A prospective study of psychophysiological arousal, acute stress disorder, and posttraumatic stress disorder.  J Abborm Psychol. 2000;  109 341-344
    PubMedGoogle Scholar
  • 188 Blanchard E B, Hickling E J, Galovski T, Veazey C. Emergency room vital signs and PTSD in a treatment seeking sample of motor vehicle accident survivors.  J Trauma Stress. 2002;  15 199-204
    CrossrefPubMedGoogle Scholar
  • 189 Ozer E J, Best S R, Lipsey T L, Weiss D S. Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis.  Psychol Bull. 2003;  129 52-73
    Google Scholar
  • 190 Zatzick D F, Russo J, Pitman R K, Rivara F, Jurkovich G, Roy-Byrne P. Reevaluating the association between emergency department heart rate and the development of posttraumatic stress disorder: a public health approach.  Biol Psychiatry. 2005;  57 91-95
    CrossrefPubMedGoogle Scholar

Dr. Jürgen Kornischka

Klinik für Psychiatrie, Psychotherapie & Psychosomatik am Klinikum Herford Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover

Schwarzenmoorstr. 70

32049 Herford

Email: juergen.kornischka@klinikum-herford.de